NCT02716818View on ClinicalTrials.gov

Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia

PHASE3CompletedINTERVENTIONAL

Enrollment

122

Participants

Timeline

Start Date

February 22, 2016

Primary Completion Date

July 28, 2018

Study Completion Date

July 28, 2018

Conditions

Congenital Adrenal Hyperplasia

Interventions

DRUG

Chronocort®

Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.

DRUG

standard glucocorticoid therapy

Subjects in this arm will continue on their standard hydrocortisone therapy

Trial Locations (1)

20892-1932

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors

lead

Neurocrine UK Limited

INDUSTRY

NCT02716818 - Comparison of Chronocort® With Standard Glucocorticoid Therapy in Patients With Congenital Adrenal Hyperplasia | Biotech Hunter | Biotech Hunter